Lv2
160 积分 2024-01-24 加入
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
7天前
已完结
Type II JAK2 Inhibitor Gets Off to a Strong Start
2个月前
已完结
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
2个月前
已完结
Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration‐Resistant Prostate Cancer: A Retrospective Study
4个月前
已完结
皖公网安备34019202002308
